Shionogi Inc. to Acquire IntraBio Inc.
October 5, 2026
Shionogi Inc., a U.S. subsidiary of Shionogi & Co., Ltd., signed an agreement to acquire all outstanding shares of IntraBio Inc. for $2.0 billion, making IntraBio a wholly owned subsidiary. The acquisition would add the approved rare-disease therapy AQNEURSA and IntraBio’s rare-disease expertise and pipeline to Shionogi’s portfolio; closing is subject to customary conditions and was planned for November–December 2026.
- Buyers
- Shionogi Inc.
- Targets
- IntraBio Inc.
- Sellers
- Existing IntraBio shareholders (individuals, trusts, and corporate entities; identities not disclosed)
- Industry
- Biotechnology
- Location
- Texas, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Biogen Acquires RayThera for Up to $1 Billion to Expand Immunology Pipeline
June 18, 2026
Healthcare Services
Biogen entered into a definitive agreement to acquire RayThera, a private immunology-focused biotechnology company, for total consideration of up to $1 billion driven by an upfront payment plus clinical and regulatory milestone payments. The deal is expected to close in the third quarter of 2026, with Biogen taking over development, manufacturing, and global commercialization of RayThera’s small-molecule anti-inflammatory assets.
-
Boehringer Ingelheim Acquires Nerio Therapeutics
August 6, 2024
Biotechnology
Boehringer Ingelheim agreed to acquire Nerio Therapeutics, a San Diego-based preclinical biotech focused on PTPN2/N1 phosphatase inhibitors for immuno-oncology, for up to $1.3 billion. Nerio was invested/incubated by Viva BioInnovator and backed by a syndicate including Avalon Ventures; the deal is intended to accelerate development of Nerio’s preclinical program as a cornerstone of Boehringer’s immuno-oncology portfolio.
-
Shionogi Inc. Acquires Qpex Biopharma, Inc.
June 26, 2023
Pharmaceuticals
Shionogi Inc., the U.S. subsidiary of Shionogi & Co., Ltd., entered into a definitive agreement to acquire San Diego-based clinical-stage antimicrobial developer Qpex Biopharma, Inc. The acquisition (upfront $100 million plus up to $40 million in milestones) brings Qpex's investigational beta-lactamase inhibitor xeruborbactam and expands Shionogi's infectious disease R&D capabilities and pipeline.
-
Alexion, AstraZeneca Rare Disease Acquires LogicBio Therapeutics
November 16, 2022
Biotechnology
Alexion, AstraZeneca Rare Disease completed its acquisition of LogicBio Therapeutics, a Lexington, Massachusetts-based genomic medicine company. The deal was implemented through a cash tender offer and a merger of an Alexion subsidiary with LogicBio, with LogicBio becoming a wholly owned subsidiary of Alexion.
-
Equillium Acquires Bioniz Therapeutics
February 16, 2022
Biotechnology
Equillium, Inc. (Nasdaq: EQ) acquired privately held Bioniz Therapeutics, obtaining exclusive worldwide rights to Bioniz's pipeline (BNZ-1, BNZ-2, BNZ-3) and proprietary discovery platform in an all-stock transaction (5,699,492 shares, ~19.3% of Equillium outstanding) plus up to $57.5M in development milestones and up to $250M in sales milestones. The acquisition expands Equillium's immunology capabilities and pipeline, adding complementary clinical-stage cytokine-targeting assets and key research and clinical personnel.
-
Shionogi Acquires Tetra Therapeutics
May 26, 2020
Biotechnology
Shionogi & Co., Ltd. agreed to acquire clinical-stage biopharmaceutical company Tetra Therapeutics, giving Shionogi global rights to Tetra's portfolio including BPN14770. The deal, announced May 26, 2020, is valued at up to $500 million in milestone and contingent payments.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.